Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Open Pilot Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly Followed Etanercept 25mg Twice Weekly, the Combination of Etanercept 25 mg Twice Weekly and Acitretin and Acitretin Alone in Patients With Moderate to Severe Psoriasis
Brief Summary: To compare the efficacy of ETN 50mg twice weekly for 12 weeks followed by reduction to a maintenance dose of 25mg twice weekly at week 24 with that of combination of ETN 25 mg Twice Weekly plus Acitretin 10mg BID at week 24 in subjects with moderate to severe psoriasis.


Options:
A: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: Etanercept + Acitretin | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Etanercept + Acitretin; Assigned to Arm(s): Group B | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Group C
B: Arm Label: Adalimumab; Type: OTHER; Interventions: Drug: adalimumab | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): Adalimumab
C: Arm Label: Part 1: Tildrakizumab 5 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Tildrakizumab 25 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 2: Tildrakizumab 5 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 2: Tildrakizumab 25 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 2: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 2: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 3: Tildrakizumab 5 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Tildrakizumab 25 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Tildrakizumab 100 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Tildrakizumab 200 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Placebo Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: tildrakizumab; Assigned to Arm(s): Part 1: Tildrakizumab 100 mg, Part 1: Tildrakizumab 200 mg, Part 1: Tildrakizumab 25 mg, Part 1: Tildrakizumab 5 mg, Part 2: Tildrakizumab 100 mg, Part 2: Tildrakizumab 200 mg, Part 2: Tildrakizumab 25 mg, Part 2: Tildrakizumab 5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part 1: Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 50 mg etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50 mg etanercept | Arm Label: 80 mg ixekizumab Dosing Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab | Arm Label: 80 mg ixekizumab Dosing Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 50 mg etanercept; Assigned to Arm(s): 50 mg etanercept | Intervention Type: DRUG; Name: 80 mg ixekizumab; Assigned to Arm(s): 80 mg ixekizumab Dosing Regimen 1, 80 mg ixekizumab Dosing Regimen 2

Answer: A